ClinicalTrials.gg
RecruitingNCT06783803ORPHADIAGUpdated Nov 12, 2026

Application of Linkage Analysis in the Identification of Novel Hereditary Factors in Familial Aneurysms

An observational study in Familial Thoracic Aortic Aneurysm and Aortic Dissection, sponsored by IRCCS Policlinico S. Donato. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by IRCCS Policlinico S. Donato · Observational

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Updated Nov 12, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Family-based
Time perspective
Cross-sectional
Enrollment
20
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to describe the effectiveness of the application of Linkage Analysis, compared to the standard procedures currently provided by the italian NHS, in the identification of thoracic aortic aneurysms and dissection (TAAD) transmission markers in individuals with familial TAAD.

Read the detailed description

According to current guidelines, it is important to screen first-degree relatives of patients with familial thoracic aortic aneurysm and dissection (FTAAD) using imaging techniques in order to detect any undiagnosed or asymptomatic cases. The current diagnostic methods for FTAAD involve clinical and instrumental diagnosis. In addition to these methods, genetic analysis through DNA testing, using a blood sample has become an essential tool. The use of massive parallel sequencing (NGS) of multiple genes or the entire exome (Whole Exome Sequencing - WES) is considered the gold standard for genetic diagnosis of FTAAD. However, it should be noted that linkage studies are not currently included in the diagnostic protocols of the Italian National Health System, although they may be helpful in complex familial cases where DNA sequencing has not provided conclusive evidence.

02

Conditions studied

  • Familial Thoracic Aortic Aneurysm and Aortic Dissection

Keywords

  • familial thoracic aortic aneurysm and dissection
  • Linkage analysis
  • biomarkers
03

In context

Lead sponsor

IRCCS Policlinico S. Donato is the lead sponsor of 105 studies on the registry; 53 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Families of patients with FTAAD in follow-up in an italian reference centre for genetic aorthopathies.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with ascending thoracic aortic aneurysms in the absence of a mutation identified by WES
  • Subjects with small and medium artery aneurysms in the absence of a mutation identified by WES
  • Relatives of individuals with ascending thoracic aortic aneurysms in the absence of a mutation identified by WES
  • Relatives of individuals with ascending thoracic aortic aneurysms in the absence of a mutation identified by WES
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Subjects wit syndromic FTAAD with WES identified gene mutation
  • Subjects wit non-syndromic FTAAD with WES identified gene mutation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Family-based
Time perspective
Cross-sectional
Enrollment
20 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • FTAAD

    members of families with FTAAD

    Diagnostic Test: Linkage Analysis

Interventions

  • Diagnostic testLinkage Analysis

    WES-Linkage analysis in families with FTAAD in follow-up in an Italian reference centre for genetic aorthopathies

06

What researchers measure

Primary outcomes

  1. DNA sequences in FTAAD

    Identify those chromosome regions containing the DNA sequences responsible for each enrolled member of FTAAD families

    Time frame: 16 months

Secondary outcomes

  1. Mutations associated with Mendelian and monogenic diseases

    Identification of potential sites for the location of the responsible gene and mutations associated with Mendelian and monogenic diseases.

    Time frame: 24 months

07

Study locations

1 of 2 sites recruiting
  • Cardiovascular Genetic Centre
    San Donato Milanese, Milan 20097, Italy
    Not yet recruiting
  • Cardiovascular Genetic Centre
    San Donato Milanese, Milan 20097, Italy
    Recruiting
08

References and documents

Publications

  • Isselbacher EM, Lino Cardenas CL, Lindsay ME. Hereditary Influence in Thoracic Aortic Aneurysm and Dissection. Circulation. 2016 Jun 14;133(24):2516-28. doi: 10.1161/CIRCULATIONAHA.116.009762. PubMed 27297344 ↗
  • Carino D, Agostinelli A, Molardi A, Benassi F, Gherli T, Nicolini F. The role of genetic testing in the prevention of acute aortic dissection. Eur J Prev Cardiol. 2018 Jun;25(1_suppl):15-23. doi: 10.1177/2047487318756433. PubMed 29708033 ↗

Individual participant data

Plan to share: No — IPD will be considered for sharing after data collection and analysis

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for May 2029, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2025
First posted
Jan 20, 2025
StartActual
Jun 15, 2024
Primary completionEst.
May 2029
CompletionEst.
Jun 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Nov 12, 2026
Sites
1 site added. Cardiovascular Genetic Centre is now Not yet recruiting
Show site
  • Cardiovascular Genetic Centre · San Donato Milanese, Italy
Nov 12, 2026
Contact
Study contact now listed: added a•••@grupposandonato.it · •••4705; added n•••@grupposandonato.it. See the current contact
Nov 12, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Cardiovascular Genetic Centre · San Donato Milanese, ItalyContact added a•••@grupposandonato.it · •••4705Contact added (no phone or email listed)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Active, not recruiting→Recruiting
    1 site added. Cardiovascular Genetic Centre is now Not yet recruiting
    Show site
    • Cardiovascular Genetic Centre · San Donato Milanese, Italy
    Contact Study contact now listed: added a•••@grupposandonato.it · •••4705; added n•••@grupposandonato.it. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Cardiovascular Genetic Centre · San Donato Milanese, ItalyContact added a•••@grupposandonato.it · •••4705Contact added (no phone or email listed)
    + 3 other changes: verification date, oversight details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06783803
Collaborators
IRCCS Ospedale San Raffaele
Responsible party
Alessandro Pini (Pincipal Investigator, IRCCS Policlinico S. Donato) — Principal investigator
First posted
Jan 20, 2025
Start date
Jun 15, 2024
Primary completion
May 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Alessandro Pini, MD
Contact
alessandro.pini@grupposandonato.it
+39 0252774705
Nathasha S Udugmpolage, Master of Science in Nursing
Contact
nathasha.udugampolage@grupposandonato.it

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion